MEI Pharma Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
LITS$0.96+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands)
| CommonShares · AdditionalPaid-InCapital · AccumulatedDeficit · TotalStockholders’Equity | |||||
|---|---|---|---|---|---|
| Balance at June 30, 2023 | 6,663 | $430,621 | $(405,997) | $24,624 | |
| Net income | — | — | 56,374 | 56,374 | |
| Share-based compensation | — | 363 | 363 | ||
| Balance at September 30, 2023 | 6,663 | 430,984 | (349,623) | 81,361 | |
| Net loss | — | — | (11,063) | (11,063) | |
| Cash dividends declared ($1.75 per share) | — | (11,660) | — | (11,660) | |
| Share-based compensation | — | 850 | — | 850 | |
| Balance at December 31, 2023 | 6,663 | 420,174 | (360,686) | 59,488 | |
| Net loss | — | — | (9,127) | (9,127) | |
| Share-based compensation | — | 668 | — | 668 | |
| Balance at March 31, 2024 | 6,663 | $420,842 | $(369,813) | $51,029 | |
| CommonShares · AdditionalPaid-InCapital · AccumulatedDeficit · TotalStockholders’Equity | |||||
|---|---|---|---|---|---|
| Balance at June 30, 2022 | 6,658 | $426,572 | $(374,159) | $52,413 | |
| Net loss | — | — | (16,624) | (16,624) | |
| Issuance of common stock for vested restricted stock units | 5 | (40) | — | (40) | |
| Share-based compensation | — | 1,559 | — | 1,559 | |
| Balance at September 30, 2022 | 6,663 | 428,091 | (390,783) | 37,308 | |
| Net income | — | — | 10,253 | 10,253 | |
| Share-based compensation | — | 813 | — | 813 | |
| Balance at December 31, 2022 | 6,663 | 428,904 | (380,530) | 48,374 | |
| Net income | — | — | (15,438) | (15,438) | |
| Issuance of warrants | — | 500 | 500 | ||
| Share-based compensation | — | 918 | — | 918 | |
| Balance at March 31, 2023 | 6,663 | $430,322 | $(395,968) | $34,354 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.